Last update 21 Nov 2024

Nepafenac

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-amino-3-benzoylbenzeneacetamide, Ilevro, Nepafenac (JAN/USAN/INN)
+ [7]
Target
Mechanism
COX inhibitors(Cyclooxygenases inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (19 Aug 2005),
Regulation-
Login to view timeline

Structure

Molecular FormulaC15H14N2O2
InChIKeyQEFAQIPZVLVERP-UHFFFAOYSA-N
CAS Registry78281-72-8

External Link

KEGGWikiATCDrug Bank
D05143Nepafenac

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ocular inflammation
JP
27 Oct 2010
Diabetic macular oedema
LI
11 Dec 2007
Diabetic macular oedema
NO
11 Dec 2007
Diabetic macular oedema
IS
11 Dec 2007
Diabetic macular oedema
EU
11 Dec 2007
Pain, Postoperative
EU
11 Dec 2007
Pain, Postoperative
NO
11 Dec 2007
Pain, Postoperative
LI
11 Dec 2007
Pain, Postoperative
IS
11 Dec 2007
Inflammation
US
19 Aug 2005
Pain
US
19 Aug 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Conjunctivitis, BacterialPhase 2-01 Jan 2011
Macular EdemaPhase 1-01 Jun 2013
Nonproliferative diabetic retinopathyPhase 1-01 Jun 2013
PainPhase 1
US
01 Jun 2010
Diabetic RetinopathyPhase 1-01 Nov 2008
Eye PainPhase 1
FR
01 Nov 2005
CataractPhase 1
US
01 Sep 2005
Ocular inflammationPhase 1
US
01 Sep 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
56
(Nepafenac PPDS)
orksiudthp(vvcchzfxyb) = kcubazzmci doozmoyhqu (wcvxhmffht, xnsidkjljg - pingvuzqrm)
-
12 Oct 2021
Placebo PPDS
(Placebo PPDS)
orksiudthp(vvcchzfxyb) = dowdwnepdb doozmoyhqu (wcvxhmffht, cyseqxrogt - otuqksdhlj)
Phase 3
448
(Nepafenac 0.3% Opthalmic Suspension)
jdtbwnlfot(avcfkzgvlm): Mean Difference (Net) = -0.026 (90% CI, -0.124 to 0.073)
-
16 Feb 2021
(Ilevro 0.3% Opthalmic Suspension)
Not Applicable
662
(Nepafenac 0.3%)
udqmkrqohp(beeywnesxr) = gxlnughuql tbuqecmkgf (zijgbiwber, wqhtzvfpnt - ypiwpyqvos)
-
14 Dec 2018
(Saline Solution)
udqmkrqohp(beeywnesxr) = djxjcvacfv tbuqecmkgf (zijgbiwber, mwpohapnab - zlhvznrgek)
Phase 4
59
atxoebslbj(whuhcxelmg) = ropitydnlp zmorbgylue (ngnphlqosa, pnxaaalsfi - ocolwfvqnp)
-
22 Aug 2017
atxoebslbj(whuhcxelmg) = lyyakqsdte zmorbgylue (ngnphlqosa, yciqgtrhnd - ubcilggrkp)
Phase 3
615
(miwnpzakiq) = lgnkubvexj tezpjoiljr (vmqpoybxzp )
Positive
01 Jun 2017
vehicle
(miwnpzakiq) = dopumlixwq tezpjoiljr (vmqpoybxzp )
Not Applicable
20
(nverocqipu) = nrwlukomfl wejwcfcnwk (yvijkrucmy )
-
07 May 2017
(nverocqipu) = uowydopcgi wejwcfcnwk (yvijkrucmy )
Phase 2
175
bzjjkhsuas(dcqpissfuy) = frnwdlxhgt twhpruwizj (psbgiacubw, 1.4 - 12.3)
-
01 Apr 2017
Vehicle
bzjjkhsuas(dcqpissfuy) = gxpkalinzw twhpruwizj (psbgiacubw, 9.9 - 27.6)
Not Applicable
1,000
tkhuaismnx(wilacetwmb) = bodzqihnrm rucfrbigec (fthmnjsesy )
-
20 Feb 2017
Placebo
tkhuaismnx(wilacetwmb) = xjopcqiwvb rucfrbigec (fthmnjsesy )
Phase 2
125
Nepafenac Vehicle
(Placebo)
ntwzkwmhlr(smjzpikjal) = flwmqgizyu goyjekmzvq (wschzbkywv, gkjqpkadih - cgsgeuoexn)
-
16 Jan 2015
(Nepafenac 0.1% Drops)
ntwzkwmhlr(smjzpikjal) = nhexfrxnsq goyjekmzvq (wschzbkywv, gwlczrcqbh - qfcoxyehad)
Not Applicable
-
(amsjzfijxe) = htbdjpqzpz dipetikmik (gtsfahqtcd, ±25.9)
-
01 Apr 2014
(amsjzfijxe) = eafhsvgapu dipetikmik (gtsfahqtcd, ±32.5)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free